Site Editor
Sandy Srinivas, MD
Sandy Srinivas, MD
Posted: Friday, July 28, 2023
Identifying disparities in the diagnosis and treatment of Hispanic subpopulations with metastatic prostate cancer is needed to further understand oncologic outcomes across subgroups. An article published in JCO Oncology Practice recently presented findings from a study examining such disparities by disaggregating race and countries of origin in men with prostate adenocarcinoma from the National Cancer Database from 2004 to 2017. Helen Y. Hougen, MD, of the University of Miami, and colleagues found that Hispanic men had greater odds of presenting with metastatic prostate cancer, were less likely to receive any treatment, and were more likely to experience treatment delays compared with non-Hispanic White men.
A total of 1,305,785 men with prostate cancer were a part of the study cohort. Of them, 4.5% (58,848) were Hispanic, and 89.7% (52,795) were White. All patients were categorized by race and ethnicity, including non-Hispanic/Hispanic Black/White and non-Hispanic/Hispanic other. Patients were also disaggregated by Hispanic country of origin including Mexico, Puerto Rico, Cuba, South/Central America, and Dominican Republic. The three main study outcomes included the rate of metastatic disease at the time of diagnosis, the rate of treatment, and treatment delays.
Overall findings revealed that Hispanic men had greater odds of presenting with metastatic prostate cancer (adjusted odds ratio [aOR] = 1.54; 95% confidence interval [CI] = 1.50–1.58; P < .001) compared with non-Hispanic White men, with the highest risk of disease presentation in Hispanic Black men (aOR = 1.68; 95% CI = 1.46–1.93; P < .01). Hispanic men were also less likely to receive any treatment (aOR = 0.60; 95% CI = 0.53–0.67; P < .001), and this effect was particularly pronounced for Dominican men (aOR = 0.52; 95% CI = 0.28–0.98; P = .044) and for Hispanic White men (aOR = 0.58; 95% CI = 0.52–0.66; P < .001). Additionally, Hispanic men were more likely to experience treatment delays (aOR = 1.38; 95% CI = 1.26–1.52; P < .001).
Disclosure: For full disclosures of the study authors, visit ascopubs.org.
JNCCN Spotlights
Resources
For your Patients
